# GLP-1 and surgery: do you have to stop before an operation?

> GLP-1s slow the stomach, which matters for anesthesia — but the guidance changed. Here's what the 2024 multi-society update actually says, the honest evidence, and the one thing everyone on a GLP-1 should do before any procedure.

**Evidence grade:** Supported but limited (rung 2 of 8 on the Peptide Evidence Ladder) · **Last reviewed:** 2026-07-02 · **Source page:** https://thepeptideera.com/evidence/glp1-and-surgery

## Short answer
If you're on a GLP-1 and have surgery, an endoscopy, or any procedure with sedation coming up, the single most important thing is simple and universal: tell your surgical and anesthesia team well in advance that you take one — and don't stop it on your own without asking them. Beyond that, the advice has actually shifted. Because GLP-1s slow how fast the stomach empties, food can remain even after normal fasting (this part is well established), which in theory raises the risk of stomach contents entering the lungs under anesthesia. But large 2025 analyses have not shown (so far, in low-certainty data) that this translates into more actual aspiration events, so in October 2024 the major societies moved away from automatically stopping the medicine for everyone toward an individualized approach: most people can keep taking it, with the team assessing risk, sometimes using a longer clear-liquid diet or a bedside ultrasound, and taking full-stomach precautions during anesthesia rather than cancelling. Whether to hold your dose is a decision for your anesthesia team and you — not a rule to apply yourself.

## Key takeaways
- Do this for sure: tell your surgery, anesthesia, or endoscopy team you take a GLP-1 — well ahead of the date. The decision to hold it or continue is theirs to make with you; never just stop (or hide) it on your own.
- The guidance changed in 2024. The 2023 “hold it before every procedure” advice was superseded in practice by a multi-society update: most people can continue, with the team assessing individual risk rather than automatically cancelling or stopping the drug.
- The mechanism is real; the actual risk is less certain. That GLP-1s leave more food in the stomach after fasting is well established — but large 2025 analyses have not shown more real aspiration events (a rare outcome, so this means “no added harm shown yet,” not “no risk”).
- It applies to sedation too — colonoscopies and endoscopies, not just operating-room surgery. Higher-risk situations include being early in dose increases, on a high or weekly dose, or having ongoing nausea/vomiting or reflux.

## Safety essentials worth knowing

These apply to GLP-1 and dual/triple-agonist medicines generally. They’re label-level points, not the full list, and not advice about you — your prescriber and the FDA label are the authority.

- **Pregnancy & breastfeeding:** these medicines are not recommended in pregnancy, and intentional weight loss is generally not advised in pregnancy; the labels advise stopping before a planned pregnancy. Breastfeeding status is a conversation to have with your clinician.
- **Birth control:** some of these medicines (such as tirzepatide) can make *oral* contraception less reliable. If you could become pregnant, ask about backup or non-oral contraception.
- **Thyroid boxed warning:** this drug class carries an FDA boxed warning (thyroid C-cell tumours seen in rodents) and is not for people with a personal or family history of medullary thyroid cancer (MTC) or MEN 2.
- **Blood sugar:** combined with insulin or a sulfonylurea, these medicines can cause low blood sugar — those other medicines often need prescriber-managed adjustment, not self-adjustment.
- **Eating disorders:** an appetite-suppressing medicine warrants particular caution with a current or past eating disorder; disclose this to your clinician.
- **Surgery, sedation & endoscopy:** because these medicines slow stomach emptying, tell your surgical or anaesthesia team you take a GLP-1 well in advance — they'll decide with you whether to continue or hold it (more: https://thepeptideera.com/evidence/glp1-and-surgery).

If you take a GLP-1 and have an operation, a colonoscopy, or anything with sedation on the calendar, you've probably seen alarming takes online — "you must stop it a week before" or "they'll cancel your surgery." The real picture is more reassuring and more nuanced than either, and the official advice actually *changed* in 2024. This page walks through what's established, what isn't, what the current guidance says, and the one thing everyone should do. It's education, not a substitute for your own care team's instructions.

## The one thing to do, no matter what

Before any procedure with anesthesia or sedation, **tell your surgeon, anesthesia team, and (for scopes) your endoscopy team that you take a GLP-1** — and do it **well in advance**, not the morning of. The decision about whether to keep taking it or hold a dose is **theirs to make with you**, based on your medicine, your dose, your symptoms, and the procedure. Two rules follow from that: **never stop the medicine on your own** without asking, and **never leave it off your medication list.** (If you take it for **type 2 diabetes**, stopping also affects your blood-sugar control — one more reason it's the team's call, not yours.) Expect the final plan to be settled **on the day**, too: the team may adjust based on how you are that morning — your symptoms, whether you fasted well, and sometimes a quick bedside ultrasound.

**Just as important, don't swing the other way:** being on a GLP-1 is **not** a reason to cancel or put off a needed operation — or a screening like a colonoscopy. It's a reason to have the conversation. The team has several ways to do the procedure safely (below), and a delayed colonoscopy or postponed surgery carries its own real risks.

**And if it's an emergency?** If you need urgent or emergency care, you may not be able to hold the drug or fast first — and **that's expected, so never delay emergency care over this.** Anesthesia teams routinely treat any emergency or unfasted patient as if the stomach is full and take airway precautions as a matter of course. This is also why carrying your GLP-1 on a medication list — or telling someone close to you — matters: so it's known even if you can't say it yourself. Everything below is context for that conversation, not instructions to self-manage.

## Why surgery teams care: the mechanism Established

GLP-1s work partly by **slowing how fast the stomach empties**. The practical consequence for anesthesia: even after the standard overnight fast, some people still have food or fluid left in the stomach. This part is well documented. In a 2024 study using bedside ultrasound, **about 56% of fasted people on a GLP-1 had retained stomach contents, versus about 19% of people not taking one.** Under anesthesia or deep sedation, the reflexes that normally protect your airway are blunted, so anything left in the stomach could, in principle, come up and get into the lungs (aspiration). That's the worry driving all of this.

## But does the retained food actually cause harm? Observational — currently unproven

Here's the honest gap that most viral advice skips. "More food in the stomach" and "more people actually harmed" are **two different claims**, and only the first is well supported. When large 2025 analyses pooled real-world data on actual **aspiration events**, they did **not** find a significant increase among GLP-1 users — the rates came out roughly the same as non-users. But read that carefully: aspiration is a **rare** event and this pooled data is **observational and graded low-certainty**, so these studies may simply be too underpowered to detect a small difference. The honest reading is **"no increased harm has been shown yet,"** not "there is no risk." The *mechanism* is real and worth respecting; what hasn't been shown is that it's translating into dangerous aspirations in the OR. That balance — real mechanism, unproven harm — is exactly why the guidance loosened rather than tightened.

## What the current guidance actually says Expert consensus

The advice has two versions, and the newer one matters:

- **2023 (the version still circulating online):** the 2023 ASA guidance advised holding the medicine before every procedure — daily doses on the day of, weekly injections about a week ahead. This was **based largely on case reports**, before the outcome data existed.
- **October 2024 (the current multi-society guidance):** this **updated the approach and, in practice, superseded** the blanket hold. Its thrust is that **most patients can continue** their GLP-1, with the team **individualizing** based on risk factors (being early in dose increases, on a high or weekly dose, or having ongoing nausea, vomiting, or reflux). When there's concern, options include a **longer clear-liquid diet before the procedure**, a **day-of stomach ultrasound**, and — importantly — treating the stomach as potentially full and taking **extra airway precautions during anesthesia rather than automatically cancelling.** The societies are candid that this is *guidance*, not a hard evidence-based rule, and that the data behind any specific "hold for X days" schedule is weak.

The takeaway for you isn't a schedule to follow — it's that a good anesthesia team has several tools here, and stopping your medicine is only one of them, chosen (or not) for your situation.

## Where it applies, and where the risk tilts higher

This isn't only about major surgery. It applies to **general anesthesia, deep or procedural sedation, and endoscopy or colonoscopy under sedation.** The considerations weigh **more** heavily if you are **early in dose escalation, on a higher or weekly-injection dose, or still having GI symptoms** like nausea, vomiting, or reflux — all signs the stomach may be emptying more slowly. They weigh less for someone long-stable on a low dose with no symptoms. Your team sorts this out; your job is to give them the information early.

## What to bring to the conversation

A few things make that pre-procedure conversation more useful — our [visit-agenda builder](/tools/visit-agenda) can assemble them:

- Which GLP-1 you take, the dose, and when your last dose was (or will be).
- Whether you've had recent nausea, vomiting, reflux, or a sense of food "sitting."
- Any recent dose increase.

For the broader picture of how these drugs affect digestion, see [GLP-1 side effects](/evidence/glp1-side-effects) and the [lesser-known effects](/evidence/glp1-lesser-known-side-effects). As always, your surgical and anesthesia team's specific instructions come first — this page is to help you have that conversation, not to replace it.

## Sources (6)
1. Sen S, et al. Glucagon-Like Peptide-1 Receptor Agonist Use and Residual Gastric Content Before Anesthesia. JAMA Surgery. 2024. — https://pmc.ncbi.nlm.nih.gov/articles/PMC10918573/ [OBSERVATIONAL]
2. Kindel TL, et al. Multisociety Clinical Practice Guidance for the Safe Use of GLP-1 Receptor Agonists in the Perioperative Period (AGA/ASMBS/ISPCOP/SAGES; ASA-affirmed). Surg Endosc. 2024. — https://pmc.ncbi.nlm.nih.gov/articles/PMC11666732/ [GUIDELINE]
3. Elkin R, et al. Association between glucagon-like peptide-1 receptor agonist use and peri-operative pulmonary aspiration: a systematic review and meta-analysis. Anaesthesia. 2025. (PMID 40230298) — https://pubmed.ncbi.nlm.nih.gov/40230298/ [META-ANALYSIS]
4. Ho J, et al. Glucagon-Like Peptide-1 Receptor Agonists and Peri-Procedural Aspiration Risk. J Endocr Soc. 2025. (PMID 40893948) — https://pubmed.ncbi.nlm.nih.gov/40893948/ [META-ANALYSIS]
5. Joshi GP, et al. American Society of Anesthesiologists (ASA) Consensus-Based Guidance on Preoperative Management of Patients on GLP-1 Receptor Agonists. Anesthesiology. 2024;140(2):346. — https://pubs.asahq.org/anesthesiology/article/140/2/346/139420/ASA-Consensus-based-Guidance-on-Preoperative [GUIDELINE]
6. Wegovy (semaglutide) — FDA Prescribing Information via DailyMed (delayed gastric emptying; consideration of aspiration risk with anesthesia/deep sedation). — https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b [LABEL]

---
From The Peptide Era (https://thepeptideera.com) — evidence-graded, primary-sourced answers about GLP-1 medicines. Education, not medical advice. No doses, no sourcing.